CSBR 8-K
Champions Oncology, Inc. (CSBR)
8-K
2024-09-11
For: 2024-09-11
View Original
Added on
April 06, 2026
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): September 11, 2024
(Exact name of registrant as specified in its charter)
| (State or Other Jurisdiction | (Commission File Number) | (IRS Employer | ||||||||||||
| of Incorporation) | Identification No.) | |||||||||||||
(Address of Principal Executive Offices)
Registrant’s telephone number, including area code: (201 ) 808-8400
N/A
(Former Name or Former Address if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||||||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||||||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||||||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | ||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
INFORMATION TO BE INCLUDED IN THE REPORT
| Item 2.02. | Results of Operations and Financial Condition. | |||||||
On September 11, 2024, Champions Oncology, Inc. (the “Company”) issued a press release regarding the Company’s unaudited financial results for its first quarter ended July 31, 2024. A copy of the Company’s press release is attached hereto as Exhibit 99.1.
The information contained under Item 2.02 in this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
| Item 9.01. | Financial Statements and Exhibits. | |||||||
(d)Exhibits
The following exhibit is filed herewith:
Exhibit No.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| CHAMPIONS ONCOLOGY, INC. | |||||||||||
| (Registrant) | |||||||||||
| Date: March 12, 2024 | By: | /s/ Ronnie Morris | |||||||||
| Ronnie Morris | |||||||||||
| Chief Executive Officer | |||||||||||
Exhibit 99.1
NEWSOne University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 551-206-8104
Champions Oncology Reports Quarterly Revenue of $14.1 Million
Adjusted EBITDA of $2.0 Million
Hackensack, NJ – September 11, 2024 – Champions Oncology, Inc. (Nasdaq: CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its first quarter of fiscal 2025, ended July 31, 2024.
First Quarter Highlights:
•Total revenue increased 12% to $14.1 million
•Margin improved to 50%
•Adjusted EBITDA of $2.0 million
•Net income of $1.3 million
Ronnie Morris, CEO of Champions, commented, “As outlined on our year-end earnings call, we’re cautiously optimistic that we’ve weathered the worst of the business downturn and we’re poised to emerge leaner and stronger. Our first quarter’s performance provided further evidence that we’re on a strategic course to more consistently deliver the results we have been striving to achieve." Morris added, “Our comprehensive platform, unique data, and strong team are the key ingredients for future growth that will drive long-term returns for our shareholders.”
David Miller, CFO of Champions, added, “The first quarter saw a return to profitability as revenue increased 12% to $14.1 million while we reduced total costs by more than $2.0 million. The revenue increase, combined with mostly unchanged cost of oncology services, lifted our margin to 50%.” Miller added, “While there will be some revenue and margin volatility over the coming quarters, our cost reductions should enable us to remain profitable on an adjusted EBITDA basis.”
Exhibit 99.1
First Fiscal Quarter Financial Results
Total revenue for the first quarter of fiscal 2025 was $14.1 million compared to $12.6 million for the same period last year, an increase of 12%. Operational improvements and efficiencies implemented in the prior year led to an increase in our bookings to revenue conversion percentage contributing to the revenue growth. Total costs and operating expenses for the first quarter of fiscal 2025 were $12.7 million compared to $15.1 million for the first quarter of fiscal 2024, a decrease of $2.4 million or 15.8%.
For the first quarter of fiscal 2025, Champions reported income from operations of $1.3 million, including $258,000 in stock-based compensation and $449,000 in depreciation and amortization expenses, compared to a loss from operations of $2.6 million, inclusive of $423,000 in stock-based compensation and $445,000 in depreciation and amortization expenses, in the first quarter of fiscal 2024. Excluding stock-based compensation, depreciation and amortization expenses, Champions reported an adjusted EBITDA income of $2.0 million for the first quarter of fiscal 2025 compared to an adjusted EBITDA loss of $1.7 million in the first quarter of fiscal 2024.
Cost of oncology services was $7.1 million for the three-months ended July 31, 2024, a decrease of $612,000, or 8.0% compared to $7.7 million for the three-months ended July 31, 2023. The decrease in cost of oncology services was primarily from a decline in outsourced lab services. For the three-months ended July 31, 2024, total margin was 49.7% compared to 38.8% for the three-months ended July 31, 2023. The improved margin resulted primarily from a combination of an increase in revenue on a lower cost base due to operational efficiencies implemented and other cost reduction initiatives.
Research and development expense for the three-months ended July 31, 2024 was $1.5 million, a decrease of $1.3 million or 47.9%, compared to $2.8 million for the three-months ended July 31, 2023. The decrease was primarily due to reduced investment in research and development, including our target discovery program. Sales and marketing expense for the three-months ended July 31, 2024 was $1.7 million, a slight decrease of $17,000, or 1.0%, compared to $1.7 million for the three-months ended July 31, 2023. General and administrative expense for the three-months ended July 31, 2024 was $2.5 million, a decrease of $413,000, or 14.0%, compared to $2.9 million for the three-months ended July 31, 2023. The decrease was primarily from a reduction in compensation and recruitment expenses.
Net cash provided by operating activities was approximately $311,000 for the three-months ended July 31, 2024 and was primarily due to our operational income, offset by net changes in our working capital accounts in the ordinary course of business. There were no investing activities for the first quarter of fiscal 2025. Net cash used in financing activities for the three-months ended July 31, 2024 was approximately $37,000 resulting from financing lease payments.
The Company ended the quarter with cash on hand of approximately $2.9 million. The Company has no debt.
Conference Call Information:
The Company will host a conference call today at 4:30 p.m. EDT (1:30 p.m. PDT) to discuss its first quarter financial results. To participate in the call, please call 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 726315, or provide the verbal reference "Champions Oncology".
Full details of the Company’s financial results will be available by or before September 16, 2024 in the Company’s Form 10-Q at www.championsoncology.com.
Exhibit 99.1
* Non-GAAP Financial Information
See the attached Reconciliation of GAAP net income (loss) to Non-GAAP net income (loss) for an explanation of the amounts excluded to arrive at Non-GAAP net income (loss) and related Non-GAAP income (loss) per share amounts for the three months ended July 31, 2024 and 2023. Non-GAAP financial measures provide investors and management with supplemental measures of operating performance and trends that facilitate comparisons between periods before and after certain items that would not otherwise be apparent on a GAAP basis. Certain unusual or non-recurring items that management does not believe affect the Company’s basic operations do not meet the GAAP definition of unusual or non-recurring items. Non-GAAP net income (loss) and Non-GAAP income (loss) per share are not, and should not, be viewed as a substitute for similar GAAP items. Champions defines Non-GAAP dilutive income (loss) per share amounts as Non-GAAP net income (loss) divided by the weighted average number of diluted shares outstanding. Champions’ definition of Non-GAAP net income (loss) and Non-GAAP diluted income (loss) per share may differ from similarly named measures used by other companies and may not be applicable for the current reporting period.
About Champions Oncology, Inc.
Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.
This press release may contain "forward-looking statements" (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties. Champions Oncology generally uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements. One should not place undue reliance on these forward-looking statements. The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors. See Champions Oncology's Form 10-K for the fiscal year ended April 30, 2024 for a discussion of such risks, uncertainties and other factors. Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and Champions Oncology's future results, levels of activity, performance or achievements may not meet these expectations. The Company does not intend to update any of the forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Champions Oncology's expectations, except as required by law.
Champions Oncology, Inc.
(Dollars in thousands)
Reconciliation of GAAP to Non-GAAP Net Income (Loss) (Unaudited)
| Three Months Ended July 31, | ||||||||||||||
| 2024 | 2023 | |||||||||||||
| Net income (loss) - GAAP | $ | 1,313 | $ | (2,566) | ||||||||||
| Less: | ||||||||||||||
| Stock-based compensation | 258 | 423 | ||||||||||||
| Net income (loss) - Non-GAAP | $ | 1,571 | $ | (2,143) | ||||||||||
Reconciliation of GAAP EPS to Non-GAAP EPS (Unaudited)
| Three Months Ended July 31, | ||||||||||||||
| 2024 | 2023 | |||||||||||||
| EPS – GAAP, basic | $ | 0.10 | $ | (0.19) | ||||||||||
| Less: | ||||||||||||||
| Effect of stock-based compensation on EPS | 0.02 | 0.03 | ||||||||||||
| EPS - Non-GAAP, basic | $ | 0.12 | $ | (0.16) | ||||||||||
| Three Months Ended July 31, | ||||||||||||||
| 2024 | 2023 | |||||||||||||
| EPS – GAAP, diluted | $ | 0.09 | $ | (0.19) | ||||||||||
| Less: | ||||||||||||||
| Effect of stock-based compensation on EPS | 0.02 | 0.03 | ||||||||||||
| EPS - Non-GAAP, diluted | $ | 0.11 | $ | (0.16) | ||||||||||
Unaudited Condensed Consolidated Statements of Operations (unaudited)
| Three Months Ended July 31, | ||||||||||||||
| 2024 | 2023 | |||||||||||||
| Oncology services revenue | $ | 14,061 | $ | 12,561 | ||||||||||
| Cost of oncology services | 7,072 | 7,684 | ||||||||||||
| Research and development | 1,454 | 2,793 | ||||||||||||
| Sales and marketing | 1,679 | 1,696 | ||||||||||||
| General and administrative | 2,527 | 2,940 | ||||||||||||
| Income (loss) from operations | 1,329 | (2,552) | ||||||||||||
| Other income | 5 | 14 | ||||||||||||
| Income (loss) before provision for income taxes | 1,334 | (2,538) | ||||||||||||
| Provision for income taxes | 21 | 28 | ||||||||||||
| Net income (loss) | $ | 1,313 | $ | (2,566) | ||||||||||
| Net income (loss) per common share outstanding | ||||||||||||||
| basic | $ | 0.10 | $ | (0.19) | ||||||||||
| and diluted | $ | 0.09 | $ | (0.19) | ||||||||||
| Weighted average common shares outstanding | ||||||||||||||
| basic | 13,593,766 | 13,506,782 | ||||||||||||
| and diluted | 14,042,379 | 13,506,782 | ||||||||||||
Condensed Consolidated Balance Sheets
| July 31, 2024 | April 30, 2024 | ||||||||||
| (unaudited) | |||||||||||
| Cash and cash equivalents | $ | 2,892 | $ | 2,618 | |||||||
| Accounts receivable, net | 9,032 | 9,526 | |||||||||
| Other current assets | 1,254 | 1,495 | |||||||||
| Total current assets | 13,178 | 13,639 | |||||||||
| Operating lease right-of-use assets, net | 5,963 | 6,252 | |||||||||
| Property and equipment, net | 5,272 | 5,721 | |||||||||
| Other long term assets | 185 | 185 | |||||||||
| Goodwill | 335 | 335 | |||||||||
| Total assets | $ | 24,933 | $ | 26,132 | |||||||
| Accounts payable and accrued liabilities | $ | 7,332 | $ | 7,960 | |||||||
| Current portion of operating lease liabilities | 1,369 | 1,337 | |||||||||
| Other current liabilities | 151 | 150 | |||||||||
| Deferred revenue | 10,312 | 12,094 | |||||||||
| Total current liabilities | 19,164 | 21,541 | |||||||||
| Non-current operating lease liabilities | 5,738 | 6,093 | |||||||||
| Other Non-current Liability | 363 | 401 | |||||||||
| Total liabilities | 25,265 | 28,035 | |||||||||
| Stockholders’ equity (deficit) | (332) | (1,903) | |||||||||
| Total liabilities and stockholders’ equity (deficit) | $ | 24,933 | $ | 26,132 | |||||||
Unaudited Condensed Consolidated Statements of Cash Flows (unaudited)
| Three Months Ended July 31, | |||||||||||
| 2024 | 2023 | ||||||||||
| Cash flows from operating activities: | |||||||||||
| Net income (loss) | $ | 1,313 | $ | (2,566) | |||||||
| Adjustments to reconcile net income (loss) to net cash provided by (used in) operations: | |||||||||||
| Stock-based compensation expense | 258 | 423 | |||||||||
| Operating lease right-of use assets | 289 | 270 | |||||||||
| Depreciation and amortization expense | 449 | 445 | |||||||||
| Allowance for doubtful accounts and estimated credit losses | (71) | 162 | |||||||||
| Changes in operating assets and liabilities | (1,927) | (2,725) | |||||||||
| Net cash provided by (used in) operating activities | 311 | (3,991) | |||||||||
| Cash flows from investing activities: | |||||||||||
| Purchases of property and equipment | — | (668) | |||||||||
| Net cash used in investing activities: | — | (668) | |||||||||
| Cash flows from financing activities: | |||||||||||
| Repurchases of common stock | — | (602) | |||||||||
| Proceeds from the exercise of stock options | — | 12 | |||||||||
| Finance lease payments | (37) | — | |||||||||
| Net cash used in financing activities: | (37) | (590) | |||||||||
| Net increase (decrease) in cash | 274 | (5,249) | |||||||||
| Cash at beginning of period | 2,618 | 10,118 | |||||||||
| Cash at the end of period | $ | 2,892 | $ | 4,869 | |||||||